Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PADCEV vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
FDA-approved: Treatment of adult patients with locally advanced or metastatic urothelial carcinoma who have received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy.,Off-label: None established.
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Approximately 3.4 days (range 2.8-4.2 days) at steady state, supporting every-3-week dosing. Terminal half-life consistent with Ig G1 clearance.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
The small molecule MMAE is metabolized primarily by CYP3A4. Enfortumab, the antibody component, is catabolized to small peptides and amino acids.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily metabolized via catabolism into small peptides and amino acids; minimal renal excretion (<5% unchanged drug in urine). No biliary/fecal data available.
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
No specific protein binding data; as a monoclonal antibody, it is not highly bound to plasma proteins (expected <10%).
Approximately 20–30% bound to plasma proteins.
Approximately 0.07 L/kg (7.0 L in 70 kg patient), indicating limited extravascular distribution and consistent with distribution into vascular and interstitial spaces.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
Administered intravenously only; bioavailability 100% by IV route.
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment recommended for mild to moderate renal impairment (e GFR ≥30 m L/min/1.73m2). Use not recommended in severe renal impairment (e GFR <30 m L/min/1.73m2) or ESRD.
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No formal studies; mild (Child-Pugh A) and moderate (Child-Pugh B) may use with caution; not recommended in severe (Child-Pugh C).
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and effectiveness in pediatric patients have not been established.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended based on age alone; monitor closely for adverse effects due to potential comorbidities and polypharmacy.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: SERIOUS SKIN REACTIONS. PADCEV can cause severe, life-threatening or fatal cutaneous adverse reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Discontinue PADCEV immediately if signs or symptoms of SJS or TEN occur and permanently discontinue if confirmed.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Cutaneous adverse reactions: Monitor for severe skin reactions; interrupt or discontinue as appropriate.,Hyperglycemia: Monitor blood glucose levels, especially in patients with diabetes or risk factors; manage with antihyperglycemics.,Ocular disorders: May cause keratitis, dry eye, or blurred vision; monitor and refer to ophthalmologist.,Peripheral neuropathy: Monitor for new or worsening neuropathy; dose adjustment may be required.,Pneumonitis or interstitial lung disease: Monitor for signs and symptoms; discontinue if confirmed.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
None.
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No specific food interactions reported. However, patients should maintain adequate hydration. Avoid grapefruit and grapefruit juice if taking concurrent CYP3A4 substrates.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
PADCEV (enfortumab vedotin) is a pregnancy category D drug. Based on its mechanism of action (MMAE-mediated disruption of microtubules), there is a potential risk of fetal harm. Advise pregnant women of the potential risk to the fetus. First trimester: Highest risk of major congenital malformations. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to MMAE's anti-mitotic effects.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
No data on presence of enfortumab vedotin or its metabolites in human milk. M/P ratio unknown. Because many drugs are excreted in human milk and due to potential for serious adverse reactions in nursing infants, advise women not to breastfeed during treatment and for at least 3 weeks after the last dose.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. The drug should be avoided during pregnancy unless the benefit outweighs risks. Physiologic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure, but no dose adjustment guidelines exist.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
PADCEV (enfortumab vedotin-ejfv) is a Nectin-4-directed antibody-drug conjugate used in locally advanced or metastatic urothelial carcinoma. Monitor for peripheral neuropathy, skin reactions, and hyperglycemia. Premedicate with antihistamines and antipyretics to reduce infusion reactions. Dose reductions may be needed for Grade 3 or higher adverse events.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
Report any new or worsening numbness, tingling, or pain in hands or feet immediately.,Monitor for signs of skin reactions such as rash, itching, or blisters, and avoid sun exposure.,Check blood glucose regularly if you have diabetes or are at risk for hyperglycemia.,Use effective contraception during treatment and for at least 2 weeks after the last dose.,Avoid live vaccines during treatment.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PADCEV vs CLADRIBINE, answered by our medical review team.
PADCEV is a Antineoplastic Agent that works by Enfortumab vedotin is an antibody-drug conjugate (ADC) directed against Nectin-4, a cell adhesion molecule expressed on urothelial carcinoma cells. The antibody portion binds to Nectin-4, leading to internalization and release of the microtubule-disrupting agent monomethyl auristatin E (MMAE) via proteolytic cleavage. MMAE binds to tubulin and inhibits microtubule polymerization, inducing G2/M phase arrest and apoptosis.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PADCEV and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PADCEV is: 1.25 mg/kg (up to 125 mg) intravenously on days 1, 8, and 15 of a 28-day cycle. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PADCEV and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PADCEV is classified as Category C. PADCEV (enfortumab vedotin) is a pregnancy category D drug. Based on its mechanism of action (MMAE-mediated disruption of microtubules), there is a potential risk of fetal harm. Ad. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.